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Abstract
Background: Mathematical modelers have given little attention to the question of how pre-exposure prophylaxis (PrEP)
may impact on a generalized national HIV epidemic and its cost-effectiveness, in the context of control strategies such as
condom use promotion and expanding ART programs.
Methodology/Principal Findings: We use an age- and gender-structured model of the generalized HIV epidemic in South
Africa to investigate the potential impact of PrEP in averting new infections. The model utilizes age-structured mortality,
fertility, partnership and condom use data to model the spread of HIV and the shift of peak prevalence to older age groups.
The model shows that universal PrEP coverage would have to be impractically high to have a significant effect on incidence
reduction while ART coverage expands. PrEP targeted to 15–35-year-old women would avert 10%–25% (resp. 13%–28%) of
infections in this group and 5%–12% (resp. 7%–16%) of all infections in the period 2014–2025 if baseline incidence is 0.5%
per year at 2025 (resp. 0.8% per year at 2025). The cost would be $12,500–$20,000 per infection averted, depending on the
level of ART coverage and baseline incidence. An optimistic scenario of 30%–60% PrEP coverage, efficacy of at least 90%, no
behavior change among PrEP users and ART coverage less than three times its 2010 levels is required to achieve this result.
Targeting PrEP to 25–35-year-old women (at highest risk of infection) improves impact and cost-effectiveness marginally.
Relatively low levels of condom substitution (e.g., 30%) do not nullify the efficacy of PrEP, but reduces cost-effectiveness by
35%–40%.
Conclusions/Significance: PrEP can avert as many as 30% of new infections in targeted age groups of women at highest
risk of infection. The cost-effectiveness of PrEP relative to ART decreases rapidly as ART coverage increases beyond three
times its coverage in 2010, after which the ART program would provide coverage to more than 65% of HIV+ individuals. To
have a high relative cost-effective impact on reducing infections in generalized epidemics, PrEP must utilize a window of
opportunity until ART has been scaled up beyond this level.
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Introduction
Antiretroviral therapy (ART) forms the basis of many HIV-
related treatment and prophylactic strategies [1]. Combination
therapies have prevented progression to AIDS and have reduced
mortality in many HIVz individuals [2,3]. The use of antiretro-
viral regimens such as zidovudine and nevirapine has been very
effective in preventing transmissions (pre- and post-partum) from
mother to child [4]. Post-exposure prophylaxis (PEP) using mostly
zidovudine is recommended for individuals following recognized
recent exposure to HIV from unprotected sex or needle use or
accidental exposure during health care. Policy makers and
researchers are now investigating ways to extend the use of
antiretroviral therapy to limit the spread of HIV at population
level.
Pre-exposure prophylaxis (PrEP) advocates the use of antiret-
roviral therapy by individuals who anticipate exposure to HIV
infection, including commercial sex workers (CSW), men who
have sex with men (MSM), and serodiscordant couples. Although
envisaged as effective protection for both men and women at risk,
it provides a promising and timely female-controlled strategy for
women at high risk [5].
Tenofovir disoproxyl fumarate (TDF) and a combination of
TDF and emtricitabine (FTC) are the focus of ongoing PrEP trials.
Their safety for treating infection within HIVz individuals has
been well established [6]. Safety trials in Cameroon, Ghana, and
Nigeria showed that once-daily oral TDF was well tolerated by
HIV{ participants over the course of their study participation.
However, there are various documented concerns regarding the
use of TDF and FTC in PrEP programs. These include the
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liver function and its consequences for those harboring the
hepatitis B virus (HBV) [7].
Results from the CAPRISA 004 trial, announced at the 2010
AIDS conference in Vienna [8], indicate that TDF-based
microbicide gel is 39% effective in preventing HIV transmission
in women [9]. A 54% reduction in new infections was observed
among women with high gel adherence. The results hold promise
for various PrEP trials that are underway to test the safety and
efficacy of TDF (and likely also for FTC) when used as a
prevention tool. The ongoing VOICE trial conducted in Uganda,
South Africa, Zambia, Zimbabwe and Malawi is a randomized
control trial comparing three oral groups (tenofovir, emtricita-
bine/tenofovir, and placebo) with two topical groups (tenofovir gel
vs placebo gel). It will be a key test of the safety and efficacy
findings of the CAPRISA 004 trial. The iPrEx trials in Brazil,
Ecuador, Peru, South Africa, Thailand and the US, and FEM-
PrEP trials in Kenya, Malawi, South Africa, Tanzania and
Zambia are also notable [10]. Assuming that all trials qualify to
advance to their final stages, i.e. if safety concerns do not emerge
and if the protective effect of PrEP is established during early
stages of these trials, it will take a number of years until guidelines
for the clinical use of PrEP are formulated.
In the meantime millions of new infections will arise, at least in
sub-Saharan Africa (SSA). An incidence projection for the South
African HIV epidemic at 2020 shows that without further
intervention, and assuming continuation of an optimistically high
rate of condom use and expansion of the national ART program,
the HIV incidence rate could still be 0.5% per year [11], which
translates to more than 200,000 new infections each year after
2020 in South Africa.
The cost-effectiveness of PrEP, a key input to PrEP guidelines, is
affected by its eventual coverage and the possibility of emerging
resistance patterns, which would require expensive resistance
management protocols that are yet to be formulated. Furthermore,
the HIV epidemics of SSA countries, where PrEP has the potential
to avert millions of new infections (roughly 2.7 to 3.2 million
estimated in [12]), are currently undergoing complex transitions. If
PrEP is integrated into long-term control strategies for generalized
epidemics in SSA, it will be introduced as one component in a
toolkit of interventions, each being scaled to achievable coverage.
It will be crucial but very difficult to demonstrate the relative
impact of PrEP on disease burden and its consequent cost-
effectiveness.
Mathematical models have been used to study the potential
impact of PrEP at the national level. Abbas et al. [12] studied the
potential role of PrEP on the future course of the HIV epidemic in
Zambia and Vissers et al. studied the potential impact in
Botswana, the Nyanza Province in Kenya and India [5]. To the
extent that these models reflect epidemic situations in resource-
limited settings, their findings point to a substantial reduction in
the number of new infections should PrEP be deployed as a
control strategy in SSA. Both papers highlight the interplay
between PrEP coverage and behavioral disinhibition as reasons for
major concern. In [12] this interplay is studied by creating
scenarios of increased sexual activity under PrEP, while [5] also
considers a decrease in condom use. Paltiel at al. [13] used a
simulation model to assess lifetime infection of high-risk groups in
the United States under different PrEP scenarios. Their work
shows that cost-effectiveness estimates depend critically on baseline
incidence assumptions.
Both [5] and [12] mention the potential impact of expanding
ART programs which do not yet provide adequate coverage to
individuals who are already infected. The focus of this paper is to
evaluate PrEP alongside ART and condom-use interventions,
informed by national HIV and demographical surveys. To this
end we have developed an age-structured model which is
contextualized to the South African epidemic, paying attention
to distribution of relative infection risks between age categories. In
South Africa, for example, the highest risk category would be 25–
35-year-old women (Fig.10 [11]).
Methods
Model Structure
The model presented here is an elaboration of an age-structured
model for the generalized HIV epidemic in South Africa [11]. It
utilizes national surveys in South Africa (2002, 2005 and 2008) to
derive parameters and tracks the overall pattern reasonably
accurately. The model was specifically designed to reflect an age
pyramid, HIV prevalence and overall mortality statistics that
would be equal to those of South Africa. In this adaptation,
individuals within the model are stratified by age, gender, disease
and treatment status: susceptible, receiving PrEP, infected,
receiving ART for treatment.
The spread of HIV is mechanistically modelled through stable
relationship formation, which is governed by the age-dependent
rate at which women change and choose their partners. The
model does not contain additional risk structure, although many
factors are linked to the rapid spread of HIV in South Africa.
These include migrant mine workers and female sex workers [14],
high age at first marriage [15] and low levels of male circumcision
[16]. These factors are indirectly accounted for by initiating the
model with high initial prevalence. The subsequent shaping of
the generalized HIV epidemic is adequately modelled by the age-
mediated heterogeneities in the model. The model tracks time
since infection, but does not incorporate a decline in infectiousness
with time since infection, as is the case in many HIV models
(e.g. [12]).
More complex HIV models have been developed for the South
African HIV epidemic. Among the most notable are those of
Johnson et al. that include age, various risk-groups, other STDs,
time since infection and other factors [17,18]. The model
presented here captures the epidemic through simpler mechanisms
and complexity without significant compromise in fitting age-
specific prevalence, mortality, behavioral and other data, including
the 2008 population survey [19].
Among other purposes, our model was originally used to study
the expanding ART program in South Africa, including a possible
expansion toward universal access to testing and treatment (UTT).
Our age-structured model (as opposed to models without
demographical detail such as the model used in Granich et al.
[20]) suggests that a lesser annual testing rate of around 20% of all
adults would be sufficient to control the epidemic within a decade
after full coverage is reached, a finding also reported in [21]. Here,
we extend our focus on the potential impact of UTT on the
generalized South African HIV epidemic to the potential impact
of PrEP, as well as examining the interplay between the two
strategies.
Introducing PrEP
The simple addition of a category of people receiving PrEP is
shown in Fig. 1 and parameter values are given in Text S1.
Susceptible individuals enroll for PrEP at a certain rate. They can
acquire infection while on PrEP, depending on its efficacy. A
fraction of susceptibles may acquire infection shortly after
initiating PrEP. (Here shortly means within one time step of the
model, which is one year.) Susceptible PrEP users can ‘drop out’
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of PrEP as a result of regular screening of PrEP users. Those who
did not get infected before discontinuing PrEP return to the
susceptible category. Those who continue PrEP use will enroll for
ART at a (typically) faster rate than they would under the
projected testing and treatment rate of the national ART program.
The transmission probability of HIV from people on PrEP or
ART to susceptible people is assumed to be 10% of that from
other HIV+ individuals.
TDF and FTC are both susceptible to one-point mutations that
can confer resistance [7]. Some researchers are concerned about
the possibility that drug-resistance resulting from the mono-
therapeutic use of these regimens could subvert ART-based
control programs [22]. However, within the relatively simple
representation included in [12], drug-resistance did not appear to
result from PrEP programs. A limited degree of drug-resistance as
a result of PrEP use is also anticipated by [23] and [24]. A recent
study investigates the interplay between PrEP use, behavior
change, and the transmission of drug-resistant strains [25]. One of
its surprising findings is that PrEP targeted to high-risk groups with
stable risk behavior could lead to a decrease in HIV transmission
and therefore to a decrease in subsequently observed levels of
drug-resistant strains. It is also worth noting that the CAPRISA
004 trial reported no detected resistance among seroconvertors
using a TDF-based microbicide gel [9].
We avoided the nuances of resistance modelling in order to
focus on the cost-effectiveness of PrEP in expanding ART (for
treatment) programs. Through regular screening, which is
included our model, the possibility of the accumulation in the
general population will be reduced.
Programmatic assumptions
If PrEP is adopted as a control strategy for generalized HIV
epidemics, it is likely that the focus will also turn to UTT. Both
PrEP (in [12]) and UTT (in [20]) are advocated as cost-effective
ways of avoiding large numbers of new infections. These
approaches must overcome similar regulatory and programmatic
challenges. Although there is currently no advocacy to use PrEP in
countries where ART treatment coverage is inadequate, it can
certainly become a contentious point, seeing that delivery channels
of these two ART-based strategies are likely to overlap.
When PrEP is promoted within certain small high-risk groups it
would limit future PrEP and ART delivery tradeoffs of using ART
for treatment (UTT) or prevention (PrEP) or both. However, at
the national level high-risk groups are both large and difficult to
identify, with CSW around mining areas a possible exception. It is
therefore reasonable to compare anticipated PrEP coverage
scenarios to those of current national ART programs and their
potential scale-up. Moreover, the efficacy and relative cost-
effectiveness of PrEP will depend on ART coverage at the time
when it is introduced.
We make a simple comparison between the coverage and
potential impact on HIV incidence of ART and PrEP programs
relative to a baseline scenario where ART coverage expands at its
current rate. The rate is chosen so that 40% of individuals, who
face competing risks of treatment or death, will enroll for ART.
This mechanism gave a reasonable fit to the total number of cases
receiving ART (Fig.8b [11]). It is assumed that both interventions
will start in 2014 and be fully scaled-up by 2019 to achieve a
specified testing and enrollment rate. It is assumed that 20% of all
confirmed susceptibles older than 15 years will enroll each year for
PrEP and that 20% of HIVz individuals will enroll for ART
under a universal test and treat scenario. We assume optimisti-
cally, following a recent finding that ART can be 90% effective in
preventing transmission [26], that PrEP is 90% effective in
preventing infection. We assume an annual drop-out rate of 1.5%
for both programs [11].
A key question for PrEP policy is whether coverage could be
decreased and the impact of PrEP maintained by targeting groups
at highest risk of infection? What is the expected impact of
expanding ART coverage on the efficacy of PrEP? We use various
scenarios to explore the sensitivity of modelled PrEP impact results
with respect to changes in parameter values which reflect PrEP
targeting, efficacy and behavioral disinhibition.
The benefits of any new interventions which reduce risk of
infection can be negated by risk compensation or behavioral
disinhibition, as demonstrated by various male-circumcision
impact studies [27,28]. For example, individuals using PrEP may
feel less need to use condoms. On the other hand, levels of condom
use may be maintained if PrEP programs include counselling and
advocacy to discourage the use of PrEP to substitute the protective
effect of condom use [5]. To evaluate the consequence of condom
substitution among PrEP users, we use different condom
substitution levels in our targeted-PrEP sensitivity analysis.
Cost assumptions
Our assumptions regarding the cost of PrEP are also kept
simple. When TDF is targeted to women this cost could include 1)
voluntary counselling (VCT) to limit the number of HIVz women
enrolled for PrEP, 2) various tests, including serum creatinine tests
to monitor renal function and detect abnormalities, hepatitis B
tests and a pregnancy test, 3) the annual cost of TDF. We make
the assumption that PrEP will be available at an annual cost of
$150 per year per person. This is based on the following unit costs:
$12 annual cost for HIV counselling and testing [29], $4 for serum
creatinine testing (the National Health Laboratory Service of
South Africa currently perform these at less than $5 per test) and
$134 for the PrEP regimen (an optimistic assumption). More
frequent testing and failure to negotiate low costs, especially PrEP
costs for large-scale PrEP programs, would increase this cost
significantly. As in [11,20] we assume that ART will be available
at an average cost (for first and second line therapy) of $600 per
year, four times the annual cost of PrEP.
Results
Universal PrEP and UTT: comparative impact
To study the impact of PrEP and UTT strategies we
constructed four scenarios. In scenario 1 there is no additional
ART coverage (i.e. no UTT) and no PrEP. In scenario 2 there is
PrEP but no UTT. In scenario 3 there is UTT but no PrEP. In
Figure 1. Simple schematic of the model. S-susceptible, I-infected,
P-receiving PrEP, I9-infected while on PrEP, A-receiving ART.
doi:10.1371/journal.pone.0013646.g001
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and UTT operates under the programmatic assumptions outlined
above.
Fig. 2a compares the coverage of non-targeted PrEP and UTT
strategies in terms of the percentage of the total population
enrolled in the respective programs. For the solid line, coverage
under the current national ART program expands with no
additional intervention. The 2004–2006 data points are from
Dorrington et al. [30] and the 2007–2008 data points are estimates
provided by WHO, UNAIDS, UNICEF [31]. In 2010 ART
coverage would be &1.4% of the total population, providing ART
to &50% of those in need. This is the 2009 coverage estimate
reported in [32], which in turn is based on STATSA estimates
which are yet to be adjusted to reflect the policy change in
eligibility criteria for pregnant women announced in December
2009. In 2025 the ART program, without any additional
intervention, will provide coverage to 3.6% of the total population
at the current rate of expansion. HIVz individuals would be
infected for an average duration of 9.6 years before initiating ART
according to our model.
UTT and PrEP coverage are shown by the dashed and dotted
lines respectively. With this UTT program 6.5% of the total
population would receive ART by 2025, initiating treatment 6.7
years after infection and reaching more of those in need of
treatment. Approximately half of the population in 2006 were
adults and close to 20% of these adults were HIVz (Fig. 2c). Thus
almost 2|6:5=20&65% of HIVz individuals would receive
ART. The PrEP program would result in almost all susceptible
adults receiving PrEP by 2025 (dotted line), dwarfing the scale of
the current ART program.
Fig. 2b shows the potential impact on aggregated HIV
incidence in the population aged 15–49. The square (resp.
diamond) is the 2008 UNAIDS (resp. ASSA) estimate for the
incidence in adults [33]. The data points serve to anchor modelled
incidence, which appears to be decreasing, and could reach 0.8%
per year by 2014 – less than half of its peak value in 2002. A recent
Figure 2. PrEP and UTT: impact and coverage at 2025. (a) Current % of adults on ART (solid line), expanded ART coverage under UTT (dashed
line) and PrEP coverage (dotted line). (b) Adult HIV incidence (age §15) in the model and 2008 UNAIDS (diamond) and ASSA (square) estimates [33].
(c) HIVz prevalence in antenatal clinics (the upperzpoints) as reported in [19] and in the population aged 15–49 (upper solid lines and vertical data
points) as reported in [33]. The lower solid line shows the prevalence of HIVz people without ART in the population aged 15–49. (d) Crude death rate.
Data from Statistics South Africa ( ) [36], Anderson et al. [37] (0), and the US Census Bureau [38] (e).
doi:10.1371/journal.pone.0013646.g002
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women was around 2% per year between 2002 and 2005 and
declined to 1.3% per year between 2005 and 2008 [34]. A
statistically significant decline in incidence of 60% could only be
established among 15–24-year-old women during this period. Our
baseline incidence curve (upper solid line) agrees with this finding.
However, the uncertainty regarding a general incidence decline
has bearing on our analysis of the cost-effectiveness of PrEP.
The impact on incidence is shown for each PrEP-ART scenario.
The comparison shows that PrEP alone will have a greater impact
on incidence than UTT alone. PrEP and UTT together will have
the biggest impact.
Fig. 2c shows the potential impact on aggregated HIV
prevalence in the population aged 15–49. The antenatal clinic
data (zpoints) for the years 1990–2008 come from the
Department of Health of South Africa [33]. The vertical data
points for the total adult prevalence come from Shisana et al. [35].
The upper solid shows modelled HIV prevalence for the
population aged 15–49. The lower solid line is the projected
prevalence of HIVz individuals without ART. The PrEP–ART
scenarios are shown in dashed lines. The model shows, as is to be
expected, no major impact on HIV prevalence by 2025 since
HIVz cases receiving treatment would still contribute to
prevalence.
Fig. 2d shows the reduction in the crude death rate under each
scenario. The   points correspond to registered deaths (Statistics
South Africa, [36]), 0 points to estimated deaths according to
Anderson et al. [37], and e points to estimates according to the
US Census Bureau [38]. Note that the crude death rate has
stabilized but that it has not yet been substantially reduced as is
expected under ART scale-up [2,3]. This might be indicating that
current ART expansion is still not reaching enough of those in
most need in South Africa – a general state of ART programs in
resource-limited settings [22].
UTT and similar strategies advocate the use of ART not to
address clinical need, but for all individuals found to be HIVz
[20,21]. Frequent testing means ART programs would reach those
in most need, averting a substantial number of deaths. Even
though PrEP has an impact on incidence, most infections are
averted among those facing low risk of mortality. A significant
reduction in the crude death rate in the first decade of PrEP
(without expanded ART coverage for treatment) is not expected.
Targeted PrEP: epidemic impact
Fig. 3 shows the impact of PrEP in terms of the expected
proportional decrease in the number of new infections in the
period 2014–2025. We assume that baseline incidence declines as
in Fig. 2b (upper solid line). Fig. 4 corresponds to Fig. 3, but
assumes a more gradual drop in incidence to 0.8% per year by
2025, based on condom use declining by 15% from 2007 onward.
The measure in each figure is shown as a function of the fraction
of all adults in the targeted population covered by PrEP at 2025
(vertical axis), ART coverage at 2025 in proportion to ART
coverage in 2010 (horizontal axis), using different combinations of
efficacy and condom substitution.
The impact among all adults when PrEP is targeted to specific
age groups is shown by vertically spaced points corresponding to
multiples of 10% in targeted PrEP coverage. Their location on the
horizontal axis indicates that ART has reached twice its 2010
coverage by 2025.
In Fig. 3a PrEP initiation is targeted to 15–35-year-old women
and is assumed to be 90% effective without leading to a decrease
in condom use. Contours represent points of equal PrEP impact.
The figure shows that 10%–25% more infections could be averted
in the targeted age group when this PrEP strategy covers 30%–
60% of women in this group. The population-level effect would be
5%–12% of all infections averted.
The additional benefit of PrEP remains independent of
expansion of the national ART program until ART coverage
reaches three times its 2010 levels. Beyond this level, which could
be reached by 2025 by a UTT strategy with an annual testing and
enrollment rate of 20% starting in 2014, the additional benefit of
PrEP decreases rapidly to the point of becoming ineffective as the
epidemic would be virtually extinct.
The model is based on the premise that heterogeneity,
particularly with respect to risk of infection, is structured by age.
An interesting policy option could be the targeting of PrEP to
narrower age groups. In Fig. 3b PrEP is targeted to 15–25-year-
old women and is assumed to be 90% effective without leading to
a decrease in condom use. At a given coverage, incremental PrEP
impact in the targeted group improves compared to Fig. 3a and
the overall impact drops marginally. For example, PrEP averts
12%–27% more infections when 30%–60% of the cohort of
women who were 15–25 years old between 2014 and 2025 use
PrEP. The population-level effect of PrEP would be less than 9%
at 60% targeted coverage.
When PrEP is targeted to 25–35-year-old women, those at
highest risk of infection in South Africa (shown in Fig. 3c), the
incremental PrEP impact in the targeted group is comparable and
the overall impact improves marginally with respect to the
scenario depicted in Fig. 3b. Here too it is assumed that PrEP
use is 90% effective in preventing infection without leading to a
decrease in condom use.
In Fig. 3d PrEP initiation is targeted to 25–35-year- old women
only, is assumed to be 70% effective and decreases condom use
among these women by 30% in addition to its decrease with age
(Fig. 5 [11]). In this scenario PrEP impact in the 25–35–year–old
target group and overall impact is about 25% less than the impact
when no condom substitution is assumed.
When baselines incidence is higher there are naturally more
infections for PrEP to avert leading to an increase in the
effectiveness of PrEP. Comparing Fig. 4a and Fig. 3a shows that
at higher baseline incidence 30%–60% PrEP coverage would avert
13%–28% more infections in the targeted group and 7%–16% of
all infections. In Fig. 3a the estimates for incidence reductions are
13%–28% in the targeted group and 7%–16% overall. Comparing
all scenarios of Fig. 4 and Fig. 3 shows that PrEP would have
between 20% and 25% greater impact in targeted groups should
higher incidence be acting from 2014–2025 than our baseline
model predicts. PrEP effectiveness in averting new infections
remains dependent on the increase in ART coverage, but greater
ART coverage must be reached before PrEP becomes ineffective.
Targeted PrEP: cost-effectiveness
From a programmatic point of view, key questions are: what is
the cost of each infection averted by a PrEP strategy and at what
level of ART coverage will cost-effectiveness arguments still favor
its use? As in [12], we perform a simple calculation of the cost per
person-years of PrEP per infection averted over the period 2014–
2025 for each PrEP strategy.
Fig. 5 shows the incremental cost-effectiveness of PrEP strategies
corresponding to those in Fig. 3. PrEP would cost more that
$20,000 in all of these scenarios. Targeting PrEP to 25–35-year-
old women in an optimistic efficacy scenario (Fig. 5c) would be
most cost-effective. The condom substitution scenario depicted in
Fig. 5d shows a decrease in const-effectiveness of about 35%–40%
relative to Fig. 5c, a scenario where no condom substitution is
assumed.
PrEP: A Window of Opportunity
PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e13646When baseline incidence is higher and when there are more
infections to avert, the cost-effectiveness of PrEP improves
significantly. The most cost-effective targeting scenario is shown
in Fig. 6c, where PrEP is targeted to 25–35-year-old women when
there is a baseline incidence of 0.8% per year at 2025. In this
scenario, the cost per infection averted could be as low as $12,000
at low ART coverage.
What these cost scenarios have in common is that an expanding
ART program would lead to a dramatic increase in the cost per
infection averted with PrEP. It appears that PrEP would have only
a window of opportunity to be cost-effective: that is until ART
coverage reaches a critical level of roughly three times the
coverage in 2010. Naturally there is uncertainty about what the
exact critical level of ART will turn out to be, as it is strongly
connected to the uncertainty in baseline incidence. However, the
existence of this critical level of ART coverage, in terms of
rendering PrEP relatively cost-ineffective, is largely independent of
baseline incidence, PrEP coverage and PrEP efficacy assumptions.
The WHO-Choice Project and the Commission on Macroeco-
nomics provide guidelines for evaluating the cost-effectiveness of
public health interventions in terms of cost per disability-adjusted
life years (DALY) saved. In terms of these guidelines, a cost per
DALY saved is said to be cost-effective if it is less than three times
the gross national income (GNI) per capita, and very cost-effective
if it is less than the GNI per capita [39,40]. The GNI per capita of
South Africa is estimated at $5,820 [41]. Therefore, if one HIV
infection averted results in 25 DALYs (a conservative estimate
which could be obtained using the method outlined in [42]), PrEP
would be judged as very cost-effective at a cost of up to
$5,820|25~$145,500 per infection averted, and cost-effective
at $5,820|3|25~$436,500 per infection averted. Indeed, most
interventions will be found to be highly cost-effective using these
guidelines [42]. Clearly, these guidelines cannot locate a
meaningful cost-effectiveness threshold on Figs. 5 and 6.
A more useful approach is to compare the cost-effectiveness of
PrEP and the number of infections it could potentially avert with
that of other interventions (Ch.15 [43]). In the model presented
here, a meaningful comparison can only be drawn with respect to
ART cost-effectiveness. Our simulations show that, assuming a
20% testing and enrollment rate from 2014 onward, ART alone
Figure 3. Percentage of new infections (cumulative between 2014 and 2025) averted due to PrEP in targeted group, in addition to
infections averted due to ART and condom use. Baseline incidence 0.5% per year at 2025. Contours in intervals of 0%, 5%, 10%, and so on.
Vertically spaced points depicts reduction in incidence among all adults. The ordinate corresponds to the 10% intervals of targeted PrEP coverage
and the co-ordinate to ART coverage in 2025 reaching twice its 2010 level.
doi:10.1371/journal.pone.0013646.g003
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of $10,000 per infection averted. This 20% annual testing rate is
relative to a baseline of current ART expansion, which is driven at
present by a testing and enrollment rate closer to 10% per year.
Thus, even if annual PrEP does indeed cost four times less than
annual ART, expanding ART would still prove more effective in
terms of cost per infection averted. While the above-mentioned
GNI-based guidelines will not judge PrEP as cost-ineffective, even
at high ART coverage levels, it is clear that the cost per infection
averted contours become tightly bunched when ART exceeds
three times its coverage in 2010. However, we showed in Figs. 2b,
3 and 4 that there could be substantial marginal benefit when
PrEP works in tandem with ART to prevent new infections.
Discussion
How should we compare PrEP and UTT? Are they competing
strategies or complementary? What are their expected relative
impacts? We should note first that PrEP is a purely preventative
strategy, whereas UTT has a dual effect. It is both a treatment and
a prevention strategy. Even if PrEP were to prove more cost-
effective than UTT as a preventative method, which appears
unlikely based on our modelled results, in practice ART coverage
would continue to expand as eligibility criteria for treatment are
relaxed. These criteria are more based on treatment guidelines
than on arguments for the cost-effectiveness of ART as a
prevention strategy.
We now turn to matters of impact, coverage and cost of
different PrEP strategies, noting the uncertainty in the impact of
such factors as HIV incidence when PrEP is introduced, annual
cost, targeting strategies and behavior change.
In theory (as suggested by Fig. 2a) non-targeted PrEP coverage
would have to be impractically high to have an effect comparable
to the effect of UTT on incidence reduction. In order to approach
disease eradication, almost all those susceptible to infection must
be protected by PrEP. However, Fig. 3a shows that targeting PrEP
initiation to 15–35 year-old women would achieve a 10%–25%
reduction in new infections by 2025 in the targeted age group.
Although optimistic in its assumptions (90% PrEP efficacy, no
condom substitution), this scenario indicates that properly
Figure 4. Percentage of new infections (cumulative between 2014 and 2025) averted due to PrEP in targeted group, in addition to
infections averted due to ART and condom use. Baseline incidence 0.8% per year at 2025. Contours in intervals of 0%, 5%, 10%, and so on.
Vertically spaced points depicts reduction in incidence among all adults. The ordinate corresponds to the 10% intervals of targeted PrEP coverage
and the co-ordinate to ART coverage in 2025 reaching twice its 2010 level.
doi:10.1371/journal.pone.0013646.g004
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In each of the targeted PrEP scenarios set out in the section
titled ‘‘Targeted PrEP: cost-effectiveness’’, the cost in person-years
of PrEP per infection averted is greater than $20,000 across a
range of PrEP coverage (Fig. 5). These estimates appear higher
than estimates in [12], where it is reported to be lower than $1,000
in optimistic targeted settings. One explanation for the difference
is the assumption of high HIV incidences, e.g. 2.4% per year in
2007 among adults in South Africa, used in [12]. Our estimate,
based on data from UNAIDS and ASSA [33] is much lower at 1%
per year in 2007 (Fig. 2b, upper solid line) and declines to 0.5%
per year by 2025. We created a simulation where baseline
incidence declines more gradually to 0.8% per year by 2025, based
on condom-use declining by 15% from 2007 onward. The results
show that the cost per infection averted could be much lower and
closer to $10,000 when ART coverage remains low and incidence
turns out to be significantly higher during the period 2014–2025.
The method we used to increase baseline incidence (by relaxing
future condom use) causes a rebounding HIV epidemic, and it
is not clear that the model can still be used in this way to establish
a convincing relationship between baseline incidence, ART
coverage and the cost-effectiveness of PrEP. It would be more
convincing to fit this model, or similar models, to different
generalized HIV epidemics with a range of baseline incidences
and HIV epidemics in different stages of retreat.
Vissers et al. [5] found that condom substitution can nullify the
benefit of PrEP in certain scenarios (when targeted to a high-risk
group at low PrEP coverage). Our analysis shows a smaller impact
of condom substitution among targeted PrEP users than was
reported in [5], which may also be related to declining incidence in
our model. However, note that while condom use in South Africa
is relatively high among 15–30-year-old women (Fig. 5 [11]), it
decreases exponentially with age (as suggested by DHS surveys in
1998, 2002, 2005, and 2008 and depicted in Fig. 5 [11]). For all
women, including those using PrEP, there will be an expected
decline in condom use over time based based on our modelling
assumptions regarding condom use. At the same time PrEP users
would move into age categories of lower sexual activity and lower
risk of infection. Risk compensation by 25–35-year-old women
using PrEP could lead to a further decrease in condom use over
the period 2014–2025, in addition to the above-mentioned
decrease-with-age effect, but this on its own will not necessarily
result in an overall increase in incidence during the period 2014–
Figure 5. Incremental cost-effectiveness ratio of PrEP: (incremental cost of PrEP)/(additional infections averted due to PrEP).
Baseline incidence 0.5% per year at 2025. Contours in intervals of $10,000| 0:5,0:75,1,    ðÞ . Contours above $50,000 are grayed out.
doi:10.1371/journal.pone.0013646.g005
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periods of time, one must consider the extra complexity of
knowing which part of this decline in condom use can be
attributed to risk compensation as opposed to aging.
In all scenarios examined, both the relative cost-effectiveness of
PrEP and its impact on incidence would certainly be considerably
reduced should UTT be introduced in South Africa shortly after
the initiation of a PrEP strategy. Even an increased rate of
expansion of the current national ART program would obscure
the benefits of PrEP.
The national ART program of South Africa is currently on a
scaling-up trajectory where less than 5% of the adult population
will receive ART by 2025 while more than 6.5% of adults (which
translates to more than 65% of HIVz cases) need to receive ART
for a significant impact on incidence to result. PrEP could serve as
a useful stop-gap control solution until ART coverage is scaled up
towards providing UTT-like coverage, after which the epidemic
may be substantially controlled in South Africa. This window of
opportunity may turn out to be long in resource-limited settings.
It is important to realize that PrEP and ART are only two of
several interventions that can be scaled up for cost-effective HIV
prevention in South Africa. Programs aimed at commercial sex
workers (CSW) and their clients, men who have sex with men
(MSM), youth education programs, male-circumcision, to name
just a few, all provide safe and very cost-effective prevention (based
on cost per DALY guidelines). Although PrEP and expanding
ART are significantly more effective, they are also more costly.
One of the key messages of the 2010 International AIDS
conference was that funding for prevention is levelling off and in
some countries decreasing [8]. It may become necessary to
determine the most cost-effective package of interventions to deal
with a generalized HIV epidemic. (Cost considerations are less of
an issue in smaller risk groups, e.g. MSM and CSW.) A follow-up
project similar to the Vissers et al. study [5] (which investigated
potential PrEP interventions in Botswana, Kenya and India),
involving expanding ART programs in different countries with
generalized HIV epidemics, would provide invaluable input to
formulating comprehensive control strategies.
Supporting Information
Text S1 Mathematical model: equations and parameter values.
Found at: doi:10.1371/journal.pone.0013646.s001 (0.08 MB
PDF)
Figure 6. Incremental cost-effectiveness ratio of PrEP: (incremental cost of PrEP)/(additional infections averted due to PrEP).
Baseline incidence 0.8% per year at 2025. Contours in intervals of $10,000| 0:5,0:75,1,    ðÞ . Contours above $50,000 are grayed out.
doi:10.1371/journal.pone.0013646.g006
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